Currently, there are still some clinical trials to be processed, for example, a clinical study of Kangfuxin (a clinically approved extract from Periplaneta americana) and FGF2 in promoting the healing of donor site and FGF1 for the treatment of coronary heart disease [99,100]. The gene discussed is FGF2; the disease is coronary artery disorder.